Chief Scientific Officer · Founder, Amaroq Therapeutics
| Role | Organisation | Sources |
|---|---|---|
| Chief Scientific Officer · Founder | Amaroq Therapeutics | Brandon Capital portfolio (9 Jun 2022), Brandon BioCatalyst portfolio (9 Jun 2022), Brandon Capital portfolio (4 Apr 2022), Brandon BioCatalyst portfolio (4 Apr 2022) |
Stories naming Dr Sarah Diermeier. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.
Case study on how CSIRO's bioinformatics teams independently validated the cancer-target findings of Amaroq Therapeutics, a New Zealand biotech whose $14m seed round was funded by the Brandon Capital-managed MRCF and others.
New Zealand cancer biotech Amaroq Therapeutics had its lncRNA drug targets independently validated by CSIRO, according to this profile, which also recalls its $14 million seed round and support from Callaghan Innovation.